A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus–associated lymphoid malignancies

Malignancies associated with latent Epstein-Barr virus (EBV) are resistant to nucleoside-type antiviral agents because the viral enzyme target of these antiviral drugs, thymidine kinase (TK), is not expressed. Short-chain fatty acids, such as butyrate, induce EBV-TK expression in latently infected B...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Perrine, Susan P., Hermine, Olivier, Small, Trudy, Suarez, Felipe, O'Reilly, Richard, Boulad, Farid, Fingeroth, Joyce, Askin, Melissa, Levy, Arthur, Mentzer, Steven J., Di Nicola, Massimo, Gianni, Alessandro M., Klein, Christoph, Horwitz, Steven, Faller, Douglas V.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2007
Assuntos:
Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1852196/
https://ncbi.nlm.nih.gov/pubmed/17119113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-01-024703
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados